Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Wong, Tsz Y ^a   Li, Fengjuan ^a   Lin, Shu mei ^d   Chan, Franky L ^b   Chen, Shiuan ^c   Leung, Lai K ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

Aromatase; Aspirin; Celecoxib; miRNA

Indexed keywords

ACETYLSALICYLIC ACID; ANDROSTENEDIONE; AROMATASE; CELECOXIB; CYCLIN A; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; MICRORNA 222; MYC PROTEIN; PROTEIN BCL XL; TRANSCRIPTION FACTOR E2F2; CYCLOOXYGENASE 2 INHIBITOR; MICRORNA; MIRN222 MICRORNA, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BREAST TUMOR; CONTROLLED STUDY; DOWN REGULATION; ESTRADIOL BLOOD LEVEL; FEMALE; LIVER WEIGHT; MCF 7 CELL LINE; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; ANATOMY AND HISTOLOGY; ANIMAL; APOPTOSIS; BLOOD; CELL CYCLE; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER; METABOLISM; ONCOGENE MYC; PATHOLOGY; TUMOR VOLUME;

ANIMALS; APOPTOSIS; AROMATASE; ASPIRIN; BODY WEIGHT; BREAST NEOPLASMS; CELL CYCLE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; E2F2 TRANSCRIPTION FACTOR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; LIVER; MCF-7 CELLS; MICE; MICRORNAS; PYRAZOLES; RNA, MESSENGER; SULFONAMIDES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903270581     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-426     Document Type: Article

References (50)

1. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182. 10.1146/annurev.biochem.69.1.145, 10966456.
2. Parente L, Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 2003, 65(2):153-159. 10.1016/S0006-2952(02)01422-3, 12504791.
3. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38:97-120. 10.1146/annurev.pharmtox.38.1.97, 9597150.
4. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999, 140(1-2):27-35.
5. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer 2003, 103(1):84-90. 10.1002/ijc.10770, 12455057.
6. Rolland PH, Martin PM, Jacquemier J, Rolland AM, Toga M. Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 1980, 64(5):1061-1070.
7. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276(21):18563-18569. 10.1074/jbc.M010787200, 11278747.
8. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med 1997, 216(2):201-210. 10.3181/00379727-216-44170, 9349689.
9. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998, 90(20):1529-1536. 10.1093/jnci/90.20.1529, 9790545.
10. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998, 90(21):1609-1620. 10.1093/jnci/90.21.1609, 9811310.
11. Sotiriou C, Lacroix M, Lagneaux L, Berchem G, Body JJ. The aspirin metabolite salicylate inhibits breast cancer cells growth and their synthesis of the osteolytic cytokines interleukins-6 and -11. Anticancer Res 1999, 19(4B):2997-3006.
12. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010, 28(9):1467-1472. 10.1200/JCO.2009.22.7918, 2849768, 20159825.
13. Alshafie GA, Abou-Issa HM, Seibert K, Harris RE. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000, 7(6):1377-1381.
14. Blumenthal RD, Waskewich C, Goldenberg DM, Lew W, Flefleh C, Burton J. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. Clin Cancer Res 2001, 7(10):3178-3185.
15. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006, 98(11):736-747. 10.1093/jnci/djj206, 16757698.
16. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003, 17(11):1547-1549.
17. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62(3):625-631.
18. Scheiman JM. Prevention of damage induced by aspirin in the GI tract. Best Pract Res Clin Gastroenterol 2012, 26(2):153-162. 10.1016/j.bpg.2012.01.005, 22542153.
19. Garcia Rodriguez LA, Cea-Soriano L, Tacconelli S, Patrignani P. Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. Recent Results Cancer Res 2013, 191:67-93. 10.1007/978-3-642-30331-9_4, 22893200.
20. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5(7):522-531. 10.1038/nrg1379, 15211354.
21. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005, 15(5):563-568. 10.1016/j.gde.2005.08.005, 16099643.
22. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007, 39(5):673-677. 10.1038/ng2003, 17401365.
23. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, Liu YP, van Duijse J, Drost J, Griekspoor A, Zlotorynski E, Yabuta N, De Vita G, Nojima H, Looijenga LH, Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006, 124(6):1169-1181. 10.1016/j.cell.2006.02.037, 16564011.
24. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838. 10.1038/nature03702, 15944708.
25. Zhou DJ, Pompon D, Chen SA. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990, 50(21):6949-6954.
26. Yue W, Zhou DJ, Chen SA, Brodie A. A New nude-mouse model for postmenopausal breast-cancer using Mcf-7 cells Transfected with the human aromatase gene. Cancer Res 1994, 54(19):5092-5095.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
28. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown M, Hammond S, Srour EF, Liu Y, Nakshatri H. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res 2009, 37(14):4850-4861. 10.1093/nar/gkp500, 2724297, 19528081.
29. Diaz-Cruz ES, Shapiro CL, Brueggemeier RW. Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005, 90(5):2563-2570. 10.1210/jc.2004-2029, 15687328.
30. Prosperi JR, Robertson FM. Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI.3 and pI.7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat 2006, 81(1-2):55-70.
31. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993, 90(3):1112-1116. 10.1073/pnas.90.3.1112, 45821, 8430082.
32. Keyomarsi K, Oleary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin-E, a potential prognostic marker for breast-cancer. Cancer Res 1994, 54(2):380-385.
33. Husdal A, Bukholm G, Bukholm IRK. The prognostic value and overexpression of cyclin A is correlated with gene amplification of both cyclin A and cyclin E in breast cancer patient. Cell Oncol 2006, 28(3):107-116.
34. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001, 15(14):2742-2744.
35. Luciani MG, Campregher C, Gasche C. Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis 2007, 28(10):2207-2217. 10.1093/carcin/bgm101, 17510082.
36. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001, 276(52):48997-49002. 10.1074/jbc.M107829200, 11585835.
37. Komatsu K, Buchanan FG, Katkuri S, Morrow JD, Inoue H, Otaka M, Watanabe S, DuBois RN. Oncogenic potential of MEK1 in rat intestinal epithelial cells is mediated via cyclooxygenase-2. Gastroenterology 2005, 129(2):577-590. 10.1016/j.gastro.2005.06.003, 16083714.
38. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004, 2(11):632-642.
39. Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 2002, 32(11):838-846. 10.1046/j.1365-2362.2002.01080.x, 12423325.
40. Redlak MJ, Power JJ, Miller TA. Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2005, 289(4):G731-G738.
41. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65(16):7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
42. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451(7175):147-152. 10.1038/nature06487, 2782491, 18185580.
43. Panda H, Chuang TD, Luo X, Chegini N. Endometrial miR-181a and miR-98 expression is altered during transition from normal into cancerous state and target PGR, PGRMC1, CYP19A1, DDX3X, and TIMP3. J Clin Endocrinol Metab 2012, 97(7):E1316-E1326. 10.1210/jc.2012-1018, 3387391, 22492871.
44. Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Ivan M, Croce CM, Nephew KP. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30(9):1082-1097. 10.1038/onc.2010.487, 3342929, 21057537.
45. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 2006, 25(46):6188-6196. 10.1038/sj.onc.1209913, 17028598.
46. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 2010, 17(2):246-254. 10.1038/cdd.2009.117, 3648637, 19730444.
47. Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L, Zhou H, Zhao RC. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009, 34(5):1461-1466.
48. Zhang J, Guo H, Zhang H, Wang H, Qian G, Fan X, Hoffman AR, Hu JF, Ge S. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer 2011, 117(1):86-95. 10.1002/cncr.25522, 2995010, 20737575.
49. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008, 283(45):31079-31086. 10.1074/jbc.M806041200, 2576549, 18790736.
50. Di Leva G, Gasparini P, Piovan C, Ngankeu A, Garofalo M, Taccioli C, Iorio MV, Li M, Volinia S, Alder H, Nakamura T, Nuovo G, Liu Y, Nephew KP, Croce CM. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst 2010, 102(10):706-721. 10.1093/jnci/djq102, 2873185, 20388878.